In this clinical study, ALECENSA was compared with crizotinib, which was the most commonly prescribed treatment for newly diagnosed people (people who hadn't been previously treated with an ALK inhibitor) with ALK+ mNSCLC. The study included people with and without ALK+ mNSCLC tumors that had spread to the brain at the start of study.
The effectiveness of ALECENSA was measured by 2 different groups of doctors. These groups of doctors are often used in clinical studies to make sure that there is a balanced review of results.
The people in the study receiving ALECENSA and crizotinib were evaluated at 2 different time points.
Learn more about the possible side effects of ALECENSA.
At the first assessment, the IRC found that, on average, people on ALECENSA lived more than twice as long without their ALK+ mNSCLC growing or spreading compared to people taking crizotinib. At this time, the Investigators were still collecting data.
The Investigators performed a follow-up assessment 10 months later once more data were available. The results from this assessment are from an exploratory analysis. This means that it was not specifically designed to find differences between ALECENSA and crizotinib. The Investigators found that the median time people taking ALECENSA lived without their disease spreading or growing was 34.8 months.
Learn more about the possible side effects of ALECENSA.
At the first assessment, the IRC evaluated the ability of ALECENSA to shrink the size of tumors in people with ALK+ mNSCLC.
It is important to know that a complete response does not mean the cancer has been cured.
The results seen with crizotinib were similar to those seen with ALECENSA.
Of the people with ALK+ mNSCLC who had a reduction in tumor size, a response to treatment for 6 months or longer was seen in:
Learn more about the possible side effects of ALECENSA.
In the first assessment, the IRC found that fewer people who took ALECENSA experienced their ALK+ mNSCLC growing in or spreading to the brain as the first place their cancer spread. This included 122 people with and 181 people without ALK+ mNSCLC tumors that had spread to the brain at the start of the study.
People in this study who did not have ALK+ mNSCLC grow or spread to the brain first may still have had their cancer spread to other parts of the body.
Learn more about the possible side effects of ALECENSA.
At the first assessment, the IRC studied reduction in tumor size in people with ALK+ mNSCLC-related brain tumors that were visible on a brain scan at the start of the study, which was part of an exploratory analysis.
It is important to know that a complete response does not mean the cancer has been cured.
Learn more about the possible side effects of ALECENSA.
Overall survival is the length of time from the start of treatment for a disease that people are still alive.
First assessment (main results to support the approval of ALECENSA):
Median overall survival was not reached for ALECENSA (meaning over half the patients were still alive at the time of the assessment).
Follow-up assessment (exploratory analysis conducted 5 years after the last patient started treatment):
Median overall survival was still not reached because 60% of patients are still alive.
The results from this follow-up assessment were not used to support ALECENSA’s approval and not specifically designed to find differences between ALECENSA and crizotinib.
First assessment (main results to support the approval of ALECENSA):
Median overall survival was not reached for ALECENSA (meaning over half the patients were still alive at the time of the assessment).
Follow-up assessment (exploratory analysis conducted 5 years after the last patient started treatment):
Median overall survival was still not reached because 60% of patients are still alive.
The results from this follow-up assessment were not used to support ALECENSA’s approval and not specifically designed to find differences between ALECENSA and crizotinib.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.